Monitoring disease burden in chronic myeloid leukemia: Past, present, and future

Egan, Daniel; Radich, Jerald P.

doi:10.1002/ajh.24381

Cited by 8 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to accurately monitor the effects of treatment, a test that can measure MRD, a small amount of which remains in the patient's body, is required, and the BCR-ABL1 mRNA test has become increasingly popular worldwide. In particular, this test has been established as an International Scale (IS) to promote the standardization of measurement methods and values, and monitoring by IS is now recommended in the guidelines of various countries [83,84]. However, molecular relapse is experienced in more than 50% of patients undergoing TKI discontinuation, even after achieving deep and undetectable MRD as measured by the BCR-ABL1 mRNA test [85][86][87].…”

Section: Leukemic Exosomesmentioning

confidence: 99%

Remodeling of Bone Marrow Niches and Roles of Exosomes in Leukemia

Yokota

Kawamoto

Gaowa

et al. 2021

IJMS

View full text Add to dashboard Cite

Leukemia is a hematological malignancy that originates from hematopoietic stem cells in the bone marrow. Significant progress has made in understanding its pathogensis and in establishing chemotherapy and hematopoietic stem cell transplantation therapy (HSCT). However, while the successive development of new therapies, such as molecular-targeted therapy and immunotherapy, have resulted in remarkable advances, the fact remains that some patients still cannot be saved, and resistance to treatment and relapse are still problems that need to be solved in leukemia patients. The bone marrow (BM) niche is a microenvironment that includes hematopoietic stem cells and their supporting cells. Leukemia cells interact with bone marrow niches and modulate them, not only inducing molecular and functional changes but also switching to niches favored by leukemia cells. The latter are closely associated with leukemia progression, suppression of normal hematopoiesis, and chemotherapy resistance, which is precisely the area of ongoing study. Exosomes play an important role in cell-to-cell communication, not only with cells in close proximity but also with those more distant due to the nature of exosomal circulation via body fluids. In leukemia, exosomes play important roles in leukemogenesis, disease progression, and organ invasion, and their usefulness in the diagnosis and treatment of leukemia has recently been reported. The interaction between leukemia cell-derived exosomes and the BM microenvironment has received particular attention. Their interaction is believed to play a very important role; in addition to their diagnostic value, exosomes could serve as a marker for monitoring treatment efficacy and as an aid in overcoming drug resistance, among the many problems in leukemia patients that have yet to be overcome. In this paper, we will review bone marrow niches in leukemia, findings on leukemia-derived exosomes, and exosome-induced changes in bone marrow niches.

show abstract

Section: Leukemic Exosomesmentioning

confidence: 99%

Remodeling of Bone Marrow Niches and Roles of Exosomes in Leukemia

Yokota

Kawamoto

Gaowa

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The remaining patients are refractory or resistant to TKIs, and they pose a significant challenge in CML [ 18 ]. The BCR::ABL1 transcript detection and quantification in peripheral blood (PB) cells using reverse transcription-quantitative PCR (RT-qPCR) and normalization to a housekeeping gene is recognized as the international standardized method for determining minimal residual disease (MRD) and plays an important role in the management of CML patients [ 19 , 20 ]. As aforementioned, the MRD level is distinguished as a major molecular response (MMR or MR3.0), with BCR::ABL1 ≤0.1% and ABL1 >10.000 copies; or a DMR (MR4.0, MR4.5, MR5.0) if BCR::ABL1 ≤0.01%, or ABL >10.000 copies when BCR::ABL1 is undetectable [ 11 ].…”

Section: Chronic Myeloid Leukemiamentioning

confidence: 99%

Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?

Bernardi,

Vallati,

Gatta

2024

Cancers

View full text Add to dashboard Cite

Artificial intelligence (AI) is emerging as a discipline capable of providing significant added value in Medicine, in particular in radiomic, imaging analysis, big dataset analysis, and also for generating virtual cohort of patients. However, in coping with chronic myeloid leukemia (CML), considered an easily managed malignancy after the introduction of TKIs which strongly improved the life expectancy of patients, AI is still in its infancy. Noteworthy, the findings of initial trials are intriguing and encouraging, both in terms of performance and adaptability to different contexts in which AI can be applied. Indeed, the improvement of diagnosis and prognosis by leveraging biochemical, biomolecular, imaging, and clinical data can be crucial for the implementation of the personalized medicine paradigm or the streamlining of procedures and services. In this review, we present the state of the art of AI applications in the field of CML, describing the techniques and objectives, and with a general focus that goes beyond Machine Learning (ML), but instead embraces the wider AI field. The present scooping review spans on publications reported in Pubmed from 2003 to 2023, and resulting by searching “chronic myeloid leukemia” and “artificial intelligence”. The time frame reflects the real literature production and was not restricted. We also take the opportunity for discussing the main pitfalls and key points to which AI must respond, especially considering the critical role of the ‘human’ factor, which remains key in this domain.

show abstract

“…The focus of this short review is on molecular diagnostic testing for the three most common BCR‐ABL1 ‐negative MPNs: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which display distinct clinical and pathologic features at presentation and exhibit different risks for progression to overt marrow fibrosis and acute myeloid leukemia. This review does not cover BCR‐ABL1 testing for chronic myeloid leukemia (CML) or CSF3R testing in neutrophilic leukemias ; for a recent review on BCR‐ABL1 testing in CML, please refer to the previous Test of the Month .…”

Section: Introductionmentioning

confidence: 99%

Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms

Xia

Hasserjian

2016

American J Hematol

View full text Add to dashboard Cite

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms characterized by recurrent somatic mutations in JAK2, CALR, and MPL. This short review addresses (1) the spectrum of mutations seen in PV, ET, and PMF, (2) the emerging genotype-phenotype correlations, (3) the current role of molecular testing in disease classification and management, and (4) several important considerations for selecting an appropriate molecular test. In our view, sequential testing algorithms and simultaneous assessment of multiple mutations by next-generation sequencing are both valid approaches to testing. Am. J. Hematol. 91:1277-1280, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Monitoring disease burden in chronic myeloid leukemia: Past, present, and future

Cited by 8 publications

References 46 publications

Remodeling of Bone Marrow Niches and Roles of Exosomes in Leukemia

Remodeling of Bone Marrow Niches and Roles of Exosomes in Leukemia

Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?

Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms

Contact Info

Product

Resources

About